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5-Hydroxytryptamine Receptor Subtypes and their 
Modulators with Therapeutic Potentials
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Abstract
         5-hydroxytryptamine (5-HT) has become one of the most 
investigated and complex biogenic amines. The main receptors and 
their subtypes, e.g., 5-HTI (5-HT1A, 5-HT1B, 5-HTID, 5-HTIE 
and  5-HT1F),  5-HT2  (5-HT2A,  5-HT2B  and  5-HT2C),  5-HT3, 
5-HT4, 5-HT5 (5-HT5A, 5-HT5B), 5-HT6 and 5-HT7 have been 
identified. Specific drugs which are capable of either selectively 
stimulating or inhibiting these receptor subtypes are being designed. 
This has generated therapeutic potentials of 5-HT receptor modu-
lators in a variety of disease conditions. Conditions where 5-HT 
receptor modulators have established their use with distinct efficacy 
and advantages include migraine, anxiety, psychosis, obesity and 
cancer therapy-induced vomiting by cytotoxic drugs and radiation. 
Discovery of 5-HT, its biosynthesis, metabolism, physiological role 
and the potential of 5-HT receptor modulators in various nervous, 
cardiovascular and gastrointestinal tract disorders, bone growth and 
micturition have been discussed in this article.
Keywords:  5-hydroxytryptamine (5-HT) receptors; Modulators; 
Biogenic amines
Introduction
       In 1930s, Erspamer began to study the distribution of 
enterochromaffin  cells,  which  stained  with  a  reagent  for 
indoles. The highest concentrations were found in gastro-
intestinal mucosa, followed by the platelets and the CNS. 
Hence the unknown indole was named entramine. Page and 
his colleges at Cleveland clinic isolate and characterize a 
vasoconstrictor substance released from clotting blood. The 
substance  was  called  serotonin  (1948).  Rapport  deducted 
that the active moiety was 5-hydroxy tryptamine, which was 
isolated as serotonin by Page. In 1952 Erspamer and Asero 
identified entramine as 5-HT. 5-HT is autacoids as well as 
important  neurotransmitter  in  CNS  and  PNS  The  neuron 
that secrets 5-HT are termed as seretonergic neurons. The 
seretonergic system is known to modulate mood, emotion, 
sleep and so it is implicated in the control of numerous be-
havioral and physiological functions. All functions are in-
volving various receptors. Fruits like banana, tomatoes, nuts, 
plumps, venoms of bees and wasps also contain 5-HT [1]. 
 
 
Biosynthesis  and  Metabolism  Pathway  and 
Distribution 
  5-HT or Serotonin is biosynthesized from tryptophan 
amino acid. Tryptophan is converted to 5 hydroxy trypto-
phan by tryptophan hydroxylase which by action of dopa 
decarboxylase  converted  into  serotonin.  This  synthesized 
serotonin is mainly stored in chramaffin and enteric neurons 
(90%). This biosynthesis not occur in CNS and Platelet but 
they take up 5-HT from circulation. 5-HT is metabolized by 
monoamine  oxidase  enzyme  (MAO)  to  5  Hydroxyindole 
acetaldehyde, which through aldehyde dehydrogenase con-
verted  into  5-Hydroxyindole Acetic Acid  (5-HIAA). This 
5-HIAA serve as marker for Malignant carcinoid syndrome 
in which higher concentration of 5-HT in body lead to 20 
fold higher excretion of 5-HIAA. 5-HT is converted into 
N-acetyl  5-HT  through  enzyme  5-HT  N-acetylase  which 
is with help of hydroxyl indole c-methyl transferase con-
verted into melatonin. Melatonin is an important hormone 
that maintains sleep cycle and also acts as antioxidant [2]. 
 
Physiological Role of Serotonin
 Serotonin (5-hydroxytryptamine) is principally found 
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stored in three main cell types - (a) serotonergic neurons 
in the CNS and in the intestinal myenteric plexus, (b) en-
terochromaffin cells in the mucosa of the gastrointestinal 
tract and (c) in blood platelets. Serotonergic neurons and 
enterochromaffin  cells  can  synthesize  serotonin  from  its 
precursor amino acid L-tryptophan, whereas platelets rely 
upon uptake of serotonin for their stores. Likewise, seroto-
nergic neurons also have the capacity for amine uptake via 
serotonin transporters. In central nervous system serotonin 
acts as neurotransmitter as well as precursor for melatonin 
hormone synthesis in pineal gland. It regulates gastrointes-
tinal motility and involved in haemostasis on platelets. The 
net effect of 5-HT is to cause platelet aggregation. It causes 
bronchoconstiction, positive inotropic and action on heart. 
All these actions are brought about by it’s interaction with 
various membrane receptors.
 
5-HT Receptor Subtypes
   Gaddum and Picarelli in 1957 first suggested that 5-HT 
receptors located on guinea pig ileum smooth muscle cells 
could be blocked by dibenzyline and the serotonin mediated 
depolarization  of  intramural  cholinergic  neuron  could  be 
blocked by Morphine. They therefore classified 5-HT recep-
tors as “D” and “M” subtypes Subsequent research demon-
strated that certain action of 5-HT like vasoconstriction in 
the carotid vessels could neither be blocked by dibenzyline 
nor by morphine such reports initiated search for other “Non 
D, Non M” receptors [3]. Peroutka and Snyder (1979) used 
radioligand  binding  study  to  classify  5-HT  receptor  sub-
types. However the classification scheme proved to be in-
valid. Hence widely accepted classification scheme is based 
on pharmacological properties, second messenger function 
and deducted amino acid sequence [4]. This classification 
scheme proposes 7 subfamilies of 5-HT receptors. 
  Table 1a, b, and c give information about the sere-
tonergic  receptor  subtypes  with  their  signal  transduction 
mechanism, their location, physiological action, agonist and 
antagonists. 
 
Theapeutic Uses of Drugs Acting on Serotonin 
Receptors
  The various indications where 5-HT receptor modula-
tors have been reported to be of beneficial are given below.
 
Central Nervous System
 
Depression
  The hypothesis in affective disorders focuses on an 
involvement  of  neurotransmitters  noradrenaline  (norepi-
nephrine), 5-HT and dopamine. It has been found that some 
depressed patients appear to have reduced cerebral concen-
tration of 5-HIAA (5-Hydroxy indole acetic acid) (the me-
tabolite of 5-HT), whereas others appear to have reduced 
level of methoxyhydroxyphenylglycerol (MHPG), a metab-
olite of noradrenaline. More consistent changes have been 
reported in the plasma concentration of L-tryptophan (the 
precursor for serotonin). The classical mechanism of anti-
depressant drugs is by increasing effective synaptic concen-
tration of monoamines-NE, 5-HT and dopamine, either by 
blocking the oxidative enzyme in synaptic terminals that de-
grade these monoamines (e.g. MAO Inhibitors) or by block-
ing the reuptake of these transmitters i.e., reuptake block-
ers.  It has been shown that many antidepressant drugs like 
imipramine,desipramine,  amitriptyline,  nortriptyline,  dox-
epin, amoxapine, maprotiline, mianserin and trazodone are 
also antagonists at 5-HT1c receptors in the brain. Selective 
5-HT reuptake inhibitors, e.g., fluoxetine, fluoxamine, par-
oxetine, citalopram and sertraline are effective as tricyclic 
anti-depressants (TCAs) and MAO-I (monoamine oxidase 
inhibitors)  in  treating  depression  of  moderate  degree  but 
probably less effective than TCAs in treating severe depres-
sion [5].
 
Psychosis
 The idea that 5-HT dysfunction could be involved in 
schizophrenia was based on the fact that LSD (Lysergic acid 
diethylamide) produce schizophrenia like symptoms. Many 
effective anti-psychotic drugs in addition to blocking dopa-
mine receptors, also act as 5-HT receptors antagonists. Clo-
zapine, an atypical anti-psychotic drug has more effect on 
limbic system and 5-HT2 receptors, which may explain its 
reduce risk of extrapyramidal symptoms [6]. Risperidone, 
which blocks both 5-HT2 and D2 receptors does improve 
both  positive  and  negative  symptoms  of  schizophrenia, 
while ritanserin, a very potent and selective 5-HT2 recep-
tor antagonist, showed significant improvement in Type II 
schizophrenics [those with primarily negative symptoms].
Drugs acting on 5-HT3 receptors e.g. ondansetron have also 
been investigated as new anti-psychotics [7].Further studies 
are required to prove their usefulness or otherwise.    
 
Migraine
 5-HT1B and 5-HT1D receptors are found mainly as 
presynaptic inhibitory receptors in basal ganglia. 5-HT1D 
receptor subtype which is expressed in cerebral blood ves-
sels  is  believed to  be  involved  in  migraine. Sumatriptan, 
5-HT1D receptor agonist is used to treat acute attack of mi-
graine. It constrict large arteries and inhibit trigeminal nerve 
transmission. Sumatriptan cause pain at site of injection and 
also cause hypertension, so contraindicated to patient with 
IHD  (Ischemic  Heart  Disease)  while  zolmitriptan  is  fast 
acting  and  don’t  cause  chest  pain.  Naratriptan,eletriptan, 
almotriptan  and  rizatriptan  are  other  agonists  of  5-HT1D 
and  5-HT1B  receptors,  active  as  antimigraine  agents  at 
lower dose than sumatriptan. They have properties similar 
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to those of sumatripan but a better bioavailability by oral 
route and are presented in the form of tablets. Their thera-
peutic use is also the treatment of migraine attacks. 5-HT2 
receptor antagonists e.g. dihydroergotamine, methysergide, 
pizotifen  and cyproheptadine are mainly use for migraine 
prophylaxis  [8].  Methysergide  is  rarely  used  because  of 
development  of  “Retroperitoneal  fibrosis”  or  “Ormond’s 
disease” which is characterize by development of fibrotic 
mass  in  peritoneal  cavity  like  kidney.  Cyproheptadine  in 
addition to 5-HT2A blocking activity also has anti-allergic 
action  due  to  histamine  receptor  antagonistic  activity  an-
timuscarinic and Ca+2 antagonistic activities. It is used in 
Receptor
Subtype
Second Messenger Location
Physiological
Action
Agonist Antagonist
5-HT1A Inhibit adenylate
cyclase and activate 
receptor operated K+ 
channel. Inhibit voltage 
gated Ca2+ channel
CNS: Raphe nuclei, 
Hippocampus 
PNS:
Cholinergic 
heteroreceptor in 
myenteric plexus 
1. Seretonergic auto 
receptor 
2. Neuronal inhibition 
3. Facilitate Ach and nor 
adrenaline release 
4. Cholinergic nerve 
terminal in myenteric 
plexus 
5. Hyperphagia (led to 
obesity)
8-OH-DPAT
Buspirone (PA)
Ipsapirone
Flesinoxan
5-CT
Quetiapine 
WAY100635
5-F 8-OH DPAT
Spiperone
Sibutramine
5-HT1B Inhibit  adenylate
cyclase
CNS:
subiculum
substania
nigra
PNS: 
Vascular smooth 
muscle
1. Seretonergic auto 
receptor
2. Terminal heteroreceptor 
to control release of Ach 
and nor adrenaline 
3. Contraction of vascular 
smooth muscle
5-CT
8-OH-DPAT
Sumatriptan
Ergotamine 
(PA) 
GR55562
SB224289
SB236057
Methiothepin
Cynopindolol
5-HT1D Inhibit adenylate
cyclase
CNS: cranial
blood   vessel 
PNS:
Vascular smooth 
muscle
1. Seretonergic auto 
receptor
2. GABAergic and 
Cholinergic heteroreceptor 
3. Vasoconstriction of 
intracranial blood vessel 
smooth muscle 
Sumatriptan
Zolmitriptan
Nortriptan
L694247
Ergotamine 
(PA)
Methiothepin 
Ergotamine
BRL15572
5-HT1E Inhibit adenylate
cyclase
CNS: cortex
striatum
PNS: m-RNA in 
vascular tissue 
Unknown 5-CT (weak 
agonist)
5-HT
Methiothepin
5-HT1F Inhibit adenylate
cyclase
CNS: Spinal cord 
hippocampus
PNS:
Uterus, mesentery, 
vascular smooth 
muscle
Trigeminal (V) neuro 
inhibition in guinea pig 
and rat
No selective agonist or antagonist are 
available
Table 1a. Seretonergic receptor subtypes
8-OH DPAT, 8-Hydroxy-2-(di-n-propylamino) Tetraline; PA, Partial Agonist; LSD, Lysergic Acid Diethylamide; 5-CT, 5 Carboxamidotryptamine; 
CSF, Cerebrospinal Fluid; 5-HT, 5 Hydroxytryptamine; CTZ, Chemoreceptor Trigger Zone
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children to enhance appetite and also reduce dumping after 
gastrin surgery (Post Gastractomy Dumping Syndrome) [9]. 
Pain
      5-HT stimulates nociceptive (pain mediating) sen-
sory nerve ending, an effect mediated by 5-HT3 receptors. 
Thus 5-HT3 receptors could play a role in nociception at 
spinal level [10]. It is further reported that 5-HT3 recep-
tor stimulation in the spinal cord results in GABA release 
that  may  inhibit  nociceptive  signal  transmission  at  sites 
post-synaptic to primary afferent terminals. These findings 
may herald the development of new non-opioid, non- ad-
dictive analgesics. The relief by 5-HT3 receptor antagonists 
in migraine and visceral discomfort associated with irritable 
bowel syndrome is known [11]. Further clinical evaluation is 
however needed to establish this concept. There is consider-
able evidence of a role for 5-HT mediation in cardiac pain. It 
has been suggested that combined antagonism of 5HT2 and 
5-HT3 receptors may provide more effective therapy for the 
treatment of angina [12].
  
Anxiety
        Buspirone is a partial agonist at 5-HT1A receptors 
used to treat various anxiety disorders.It shows high specific 
Receptor
Subtype
Second Messenger Location
Physiological
Action
Agonist Antagonist
5-HT2A
D receptor
Phospholipase C  
activation
CNS: cerebral cortex 
PNS: GI, vascular 
and bronchial smooth 
muscle, platelets
1. Neuro excitation 
2. Broncho constriction 
3. Platelet aggregation
4. Smooth muscle 
contraction 
α-methyl 5-HT
5-CT
Sumatriptan
8-OH DPAT
LSD
Ketanserin 
Cyproheptadin
Pizotifin 
Methylsergide
Risperidone
Olanzapine 
Clozapine 
5-HT2B Phospholipase C 
activation
CNS: cerebellum 
hypothalamus
PNS: Vascular 
endothelium,
stomach 
Endothelium dependant 
vaso relaxation via NO 
production and stomach 
fundus contraction
5-CT
Sumatriptan
BW723C86
RS127445
SB204741
5-HT2C Phospholipase C 
activation
CNS: choroid plexus,
hippocampus, 
hypothala-mus
Modulation of transferin 
production and modulation 
of CSF volume
α -methyl 5-HT
5-CT
Quipazine
Methylsergide
Olanzapine 
Mesulergine 
5-HT3
M receptor
Ligand gated ion  
channel
CNS: 
area postrema 
PNS: Abdominal 
visceral afferent neuron
1. Stimulate vomiting by 
acting on CTZ  and by 
vagal neuro excitation 
2. Stimulate nociceptive 
(pain mediating) nerve 
ending led to pain 
2-me5-HT
5-MeOT
Ondensetron
Tropisetron
Granisetron
5-HT4 Activation of 
adenylate cyclase
CNS: 
Hippocampus
PNS: GIT
Neuronal excitation
Increase GI motility
Mosapride
Cisapride
Zacopride 
GR113808
SB204070
5-HT5A     Unknown CNS: olfactory bulb, 
Hebenula
Unknown No selective agonist or antagonist 
are available
5-HT5B     Unknown CNS: olfactory bulb, 
Hebenula
Unknown No selective agonist or antagonist 
are available
Table 1b. Seretonergic receptor subtypes
8-OH DPAT, 8-Hydroxy-2-(di-n-propylamino) Tetraline; PA, Partial Agonist; LSD, Lysergic Acid Diethylamide; 5-CT, 5 Carboxamidotryptamine; 
CSF, Cerebrospinal Fluid; 5-HT, 5 Hydroxytryptamine; CTZ, Chemoreceptor Trigger Zone
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for 5-HT1A  receptors, which are inhibitory autoreceptors 
that reduce the release of 5-HT and other mediators. Buspi-
rone and related compounds ipsapirone and gepirone don’t 
cause sedation or motor in coordination nor have withdrawal 
effects as with other anxiolytics like barbiturates [13].
 
Parkinsonism
  Of the three cardinal symptoms of parkinsonism, i.e., 
rigidity, tremor and bradykinesia, tremor may be mediated 
by 5-HT2 receptors. This was revealed by the success of ri-
tanserin, a potent and selective 5-HT2 receptor antagonist, in 
reducing the tremor of parkinsonism patients [14].
 
Treatment of drug abuse
 5HT3 receptor antagonism has also been shown to re-
duce the alcohol intake in animals and in human .However, 
more preclinical and clinical studies are required, to arrive 
at any meaningful conclusion about the usefulness of 5-HT3 
receptor blockers in treatment of drug abuse [15].
 
Tempreture regulation
  Changes  in  temperature  were  determined  follow-
ing  injection  of  noradrenaline,  adrenaline,  isoprena-
line,  dopamine  and  5-hydroxytryptamine  (5-HT)  into 
the  cerebral  ventricles  of  the  conscious  mouse.  5-HT 
(10-160 µg) caused a fall in body temperature. The activ-
ity  may  be  involving  5-HT2  receptor.Hence  5-HT  could 
be  the  effective  target  to  control  body  temperature  [16]. 
 
Anti-emetic Action
 The central neural regulation of vomiting is vested in 
two separate units in medulla. These are vomiting centers 
and chemoreceptor trigger zone(CTZ).Impulses from CTZ 
pass to vomiting centre and integrate the visceral and somat-
ic functions involved in vomiting .The main neurotransmit-
ters considered to be involved in the control of vomiting are 
acetylcholine, dopamine, histamine and 5-HT.Receptors for 
these neurotransmitters have been demonstrated in relevant 
areas.5-HT3 receptors in brain particularly in the area pos-
trema, a region of medulla in the vomiting reflex, and se-
lective 5-HT3 receptor antagonists are useful as anti-emetic 
drugs [17]. Ondansetron, tropisetron and dolasetron are of 
particular value in preventing and treating vomiting cause 
either by radiation therapy in cancer patients or by adminis-
tration of cytotoxic drugs such as cisplatin [17].
 
Gastrointestinal tract
  5-HTIA, 5-HTlc, 5-HT2, 5-HT3 and 5-HT4 receptors 
have been identified in the gut, in either the enteric nervous 
system or on smooth muscles [18-20]. The actions of 5-HTI-
like receptors may include inhibition of release and smooth 
muscle contraction. 5-HT2 receptors located on the smooth 
muscle  cells,  when  stimulated  directly  cause  contraction 
of gastrointestinal smooth muscle and gut vascular smooth 
muscle. Some selective 5-HT2 receptor agonists stimulate 
contraction of the lower oesophageal sphincter [21]. 5-HT3 
receptors are located on post-synaptic enteric and sensory 
neurones, on enteric neuronal membranes, in the vagus, on 
gastric endocrine glands and in the CNS.  They are impli-
Receptor
Subtype
Second 
Messenger
Location
Physiological
Action
Agonist Antagonist
5-HT6 Activation 
of adenylate 
cyclase
CNS: caudate 
putamen, 
hippocampus
PNS: Superior 
cervical ganglia 
Modulation of 
CNS Ach release
No selective 
agonist  
available
SB271046
Methiothepin 
5-HT7 Activation of 
adenylate 
cyclase
CNS:
hypothalamus
 PNS:
gastrointestinal and 
vascular smooth 
muscle
Smooth muscle 
relaxation 
5-HT
Sumatriptan
8-OH DPAT
SB258719
Methiothepin
Table 1c. Seretonergic receptor subtypes
8-OH DPAT, 8-Hydroxy-2-(di-n-propylamino) Tetraline; PA, Partial Agonist; LSD, Lysergic Acid Diethylamide; 5-CT, 5 Carboxami-
dotryptamine; CSF, Cerebrospinal Fluid; 5-HT, 5 Hydroxytryptamine; CTZ, Chemoreceptor Trigger Zone
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cated in the modulation of cholinergic transmission in the 
enteric  nervous  system,  where  their  stimulation  has  been 
reported  to  facilitate  acetylcholine  (ACh)  release.  5-HT4 
receptors are believed to be located in the nerve terminals 
on both cholinergic interneurones and motor neurones. Their 
stimulation leads to increased release of ACh and they ac-
celerate upper gastrointestinal transit as well as increase in 
colonic motor activity [22].
 
Irritable bowel syndrome (IBS)
  5-HT4 agonists increase intestinal motility and could 
be used in the treatment of gastroesophageal reflux, intes-
tinal paresis (constipation), irritable bowel syndrome. The 
first drug of this group is tegaserod. A frequent adverse ef-
fect of tegaserod is diarrhea and a rare more severe effect is 
ischemic colitis. Depending on whether diarrhoea or consti-
pation is the presenting problem, IBS is sub-classified as ei-
ther diarrhoea predominant IBS or constipation predominant 
IBS. Though the exact pathophysiology remains unclear, it 
has been reported that patients of IBS have a higher resting 
tone of the intestinal smooth muscles and have an excessive-
ly sensitive colon. Patients with IBS may also in some cases 
have a reduced tolerance to gas infusion into the small bow-
els and the threshold for perception of intestinal contraction 
may be lower than normal [23]. 5-HT3¬ receptor blockade 
has been shown to slow colonic transit in healthy volunteers 
and has also been reported to reduce visceral hypersensitiv-
ity [24].Thus 5-HT3 receptor antagonists like ondansetron 
were thought to be of benefit in diarrhea predominant IBS 
cases. Stimulation of 5HT4 receptors facilitate cholinergic 
neurotransmission in the gut and thereby increase colonic 
motor activity. Thus, 5HT4 receptor agonists like cisapride, 
zacopride, renzapride have a potential role in the constipa-
tion predominant IBS patients [25].  
 
Malignant carcinoid syndrome
  Carcinoid syndrome is a rare disorder associated with 
malignant tumors enterochrommafin cells, usually arising in 
the small intestine and metastatising to liver. These tumors 
secreate variety of hormones. 5-HT is the important one. The 
syndrome is readily diagnosed by measuring excretion of 
5-HIAA(5-hydroxyindole acetic acid);the main metabolite 
of 5-HT in the urine. The concentration of which increase 
up to 20-fold. 5-HT2 antagonists such as cyproheptadine are 
effective in controlling some of the symptoms of carcinoid 
syndrome. A complemantary therapeutic approach is to use 
a long acting analogue of somatostatin analogue, namely oc-
treotide, which suppress the hormone secretion from various 
neuroendocrine cells, including carcinoid cells [26].
 
Dyspepsia
  Dyspepsia is defined as pain or discomfort centered in 
the upper abdomen in the absence of any structural or bio-
chemical abnormality. 5-HT3 receptor antagonists have been 
reported to reduce visceral pain reflex in the gut, and studies 
in the rat showed that granisetron and tropisetron (but not 
ondansetron) reduced the pain response induced by duodenal 
distension [27]. Thus 5-HT3 receptor antagonists would the-
oretically benefit patients of dyspepsia who have increased 
visceral sensitivity. 
 
Non-cardiac chest pain
  Sometimes referred to as chest pain of undetermined 
etiology (CPUE), it is an ill defined entity requiring urgent 
elimination  of  other  differential  diagnosis.  Some  authors 
have  reported  that  visceral  nociceptive  abnormalities  in 
the oesophagus may contribute in the etiopathogenesiss of 
CPUE [28]. As 5-HT3 receptor antagonists can reduce the 
visceral pain reflex in the gut, they would theoretically be of 
benefit in the management of such cases.
 
Gastro-oesophageal reflux disease
  The symptoms of pain and anxiety, seen in gastroo-
esophageal reflux disease (GERD) are due to a pathologi-
cal acid reflux into the oesophagus which may result from 
a  combination  of  decreased  lower  oesophageal  sphincter 
tone and impaired acid clearance [29, 30]. 5-HT4 receptor 
agonists having prokinetic action have been found clinically 
useful in such conditions.
 
Cardiovascular system
    Ketanserin,  a  5-HT2  receptor  antagonist  with  high 
affinity for peripheral 5-HT2 sites, reduces blood pressure 
by causing vasodilation and reducing total peripheral resis-
tance. The reflex tachycardia seen with other vasodilators is 
not seen with ketanserin [31].This 5-HT2 receptor blockade 
may be very useful in protecting the microcirculatory bed 
against the detrimental effects of serotonin, which is mas-
sively released by aggregation of platelets, particularly when 
the vascular bed is predamaged by atherosclerosis, diabetes 
mellitus and old age. Ketanserin has also been reported to be 
more effective in the elderly [32].
 
Ophthalmology
  5-HT receptor modulators may have some potential in 
the treatment of ocular conditions such as glaucoma. A sin-
gle topical application of 0.5 % ketanserin, a 5-HT2 receptor 
antagonist with additional alpha-l adrenoceptor blocking ac-
tivity, has recently been reported to lower intra-ocular pres-
sure (IOP) for 6-8 hours. This decrease in IOP was due to 
increased outflow and was not accompanied by any change 
in systolic or diastolic blood pressure, heart rate, pupil size, 
corneal thickness or tear secretion [33].
 
Diabetes 
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  In overnight fasted rats 5-HT was found to produce 
dose dependant increase in serum glucose level. 5-HT may 
cause hyperglycemia as shown in Figure 1. It has been re-
ported that 5-HT2A receptor agonist α methyl 5-HT increase 
serum glucose while 5-HT2A receptor antagonist sarprogra-
late reduce serum glucose level. In same study 5-HT3 re-
ceptor agonist 1-Phenyl biguanide potentiate hyperglycemia 
effect of 5-HT while 5-HT receptor antagonist ondensetron 
inhibit the same action [34, 35].
 
Obesity 
  Sibutramine  is  an  inhibitor  of  5-HT/Noradrenaline 
reuptake at the hypothalamic sites that regulate food intake. 
Sibutramine reduce food intake and cause dose dependant 
weight loss, the weight loss being associated with decrease 
in obesity related risk factors [36, 37].
 
Bone growth
  Selective  serotonin-reuptake  inhibitors  (SSRIs)  an-
tagonize  the  serotonin  (5-hydroxytryptamine)  transporter 
(5-HTT), and are frequently prescribed to children and ad-
olescents to treat depression. However, recent findings of 
functional serotonergic pathways in bone cells and prelimi-
nary clinical evidence demonstrating detrimental effects of 
SSRIs on bone growth. The current work investigated the 
impact of 5-HTT inhibition on the skeleton in: (a) mice with 
a null mutation in the gene encoding for the 5-HTT; and (b) 
growing mice treated with a SSRI.  In both models, 5-HTT 
inhibition had significant detrimental effects on bone miner-
al accrual. 5-HTT null mutant mice had a consistent skeletal 
phenotype of reduced mass, altered architecture, and inferior 
mechanical properties, whereas bone mineral accrual was 
impaired in growing mice treated with a SSRI. These phe-
notypes resulted from a reduction in bone formation without 
an increase in bone resorption and were not influenced by 
effects on skeletal mechanosensitivity or serum biochem-
istries. These findings indicate a role for the 5-HTT in the 
regulation of bone accrual in the growing skeleton and point 
to a need for further research into the prescription of SSRIs 
to children and adolescents [38].
 
Micturition
  Traditionally, central 5-HT-pathways are considered to 
be inhibitory in the control of micturition. However, at least 
in the rat, 5-HT1A and 5-HT7 receptors have excitatory ac-
tions. The use of antagonists for these two receptors indicates 
that both play an essential role in micturition in the rat and 
probably in the guinea pig. Interestingly, both receptors seem 
to have a similar role supraspinally, although they have op-
posing effects on adenylyl cyclase. The paucity of evidence 
compared with rat indicating that 5-HT plays an important 
role in the control of micturition may just reflect the lack 
of experiments carried out in this species. Overall the data 
indicate that 5-HT is an important transmitter involved in 
the control of micturition. However, further experiments are 
required to elucidate its precise role and the seeming differ-
ence in importance it has in this function between species 
[39].
 
 
Conclusions
  Basic scientific research has expanded at a great pace, 
and more and more potent and selective agonists and an-
tagonists for different 5-HT receptor subtypes are discov-
ered. The study at molecular level revealing more subtypes 
of each receptor family. Scientists are finding precise and 
specific involvement of such receptor subtypes in different 
physiological processes and pathological states. Therefore, 
drugs acting specifically on 5-HT, suggesting their therapeu-
tic potentials in conditions either in CNS or in peripheral tis-
sues. The 5-HT receptor modulating drugs have now estab-
lished their therapeutic role in various disease conditions like 
emesis, anxiety and migraine, in various other neurological 
conditions , as well as peripheral disorders. More studies in 
future will guide therapeutic potential of 5-HT modulating 
drugs in other conditions.
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